Corbus Pharmaceuticals Holdings, Inc. (CRBP)
- Sector
- Biotechnology
- Last price
- $4.78
- As of
Kresmion compiles this page from CRBP's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Corbus Pharmaceuticals Holdings, Inc. (CRBP): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-15.
See the full CRBP dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CRBP on one page. Preview it with sample data, then open it live with a free account.
Preview the CRBP dossierActive signals for CRBP
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 41.1%, EPS $-1.81 vs $-1.2832 estimate
- highCONSENSUS_SELL
3 tracked funds reduced CRBP this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 67% of CRBP (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +63% to CRBP (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +102% to CRBP (2026Q2)
FREE, NO ACCOUNT
Every signal on CRBP, as it fires
You are seeing 5 of 10 signals recorded on CRBP since 2026-05-26.
The five above landed across 2 days. The other 5 were recorded on 1 other days. 5 of the 10 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CRBP (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 21833P301 · 2026Q2 | $1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 21833P301 · 2026Q2 | $864K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 21833P301 · 2026Q2 | $107K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CRBP
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
CRBP against its peers
CRBP's return on equity of -53.2% ranks in the 84th percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-01-31.
| Metric | CRBP | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 2.0M | n/a | 11 |
| Operating margin | n/a | -313.9% | n/a | 10 |
| Net margin | n/a | -404.1% | n/a | 11 |
| Return on equity | -53.2% | -89.9% | 84 | 15 |
| 1 year | -70.7% | -20.8% | 8 | 18 |
Peers (22): AARD, PMN, CRDF, TNYA, NTRB, CGTX, EQ, ACRV, ICCC, NRXS, ONCY, RLYB, IMUX, OKUR, BMEA, PTHS, PLYX, RANI, KZIA, NTHI, ATRA, OSTX. Left out: TELO (no annual filing), RTSN (no annual filing), OKYO (period gap). Fiscal periods ending between 2025-06-30 and 2026-01-31. Every figure is one full fiscal year read from one annual filing (CRBP: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CRBP on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CRBP for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.